Plato Investment Management Ltd Sells 17,273 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Plato Investment Management Ltd cut its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 27.2% in the 4th quarter, HoldingsChannel reports. The fund owned 46,257 shares of the company’s stock after selling 17,273 shares during the period. Plato Investment Management Ltd’s holdings in Teva Pharmaceutical Industries were worth $1,023,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Smithfield Trust Co grew its position in Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after purchasing an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Teva Pharmaceutical Industries in the 3rd quarter worth about $50,000. Venturi Wealth Management LLC bought a new stake in Teva Pharmaceutical Industries in the 3rd quarter worth about $60,000. Ameliora Wealth Management Ltd. bought a new stake in Teva Pharmaceutical Industries in the 4th quarter worth about $66,000. Finally, Farther Finance Advisors LLC grew its position in Teva Pharmaceutical Industries by 273.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,538 shares of the company’s stock worth $82,000 after purchasing an additional 3,323 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now directly owns 695,000 shares in the company, valued at $15,296,950. This represents a 29.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.55% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $16.01 on Tuesday. The stock has a market capitalization of $18.15 billion, a P/E ratio of -11.04, a PEG ratio of 1.44 and a beta of 0.71. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The firm’s 50 day moving average is $19.41 and its 200 day moving average is $18.46. Teva Pharmaceutical Industries Limited has a 12 month low of $12.51 and a 12 month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on TEVA. UBS Group reduced their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Barclays dropped their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. Finally, StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and a consensus price target of $23.57.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.